Pooled analysis shows no 4-year mortality risk with low-dose PCB

281144

Sumary of Pooled analysis shows no 4-year mortality risk with low-dose PCB:

  • In a pooled analysis of two randomized controlled trials of a low-dose paclitaxel-coated balloon to treat peripheral artery disease, there was no mortality difference between the paclitaxel-coated balloon and an uncoated balloon at 4 years..
  • As Healio previously reported, a summary-level meta-analysis published in December 2018 showed that patients treated with paclitaxel-coated devices had higher rates of long-term mortality than controls..
  • Thoracic Institute, presented a pooled analysis of mortality data from two randomized controlled trials of a low-dose paclitaxel-coated balloon (PCB;.
  • The ILLUMENATE EU randomized controlled trial and the ILLUMENATE Pivotal IDE trial included a combined 589 patients (PCB group, median age, 67 years;…

Want to know more click here go to health news source.

From -

Close

Languages